CONTENTS

3 Our Impact
4 Letter from the Chairman
5 Message from the President
6 Fundraising Highlights
7 Extraordinary Measures
8 Ways to Give
9 Research and Grants Update
10 Researcher Spotlight
11 Patient Spotlights
12 Funded Researchers
14 Donor Recognition
21 Gateway Board
22 Financial Highlights
ABOUT GATEWAY

Gateway for Cancer Research funds practice-changing discoveries in cancer care by harnessing the unrelenting passion of the research community and empowering informed patients to triumph over their disease. Gateway awards grants to clinician-scientists that advance early-stage clinical trials at the vanguard of discovery science, bringing breakthroughs to the bedside for patients around the world.

All of this is guided by a clear vision:
To create a world in which a cancer diagnosis is no longer feared.

OUR CHALLENGE

Cancer is a complex, global, public health threat that requires a global response. Ending cancer as we know it requires a shared vision and collective drive of researchers, physicians and philanthropists to bring to life the novel ideas that lead to transformational breakthrough therapies and cures.

Together, we are the gateway to hope for more than 18 million people in the world who receive a cancer diagnosis each year.

OUR IMPACT

At Gateway, it is always and only about the patient. An astonishing 99 cents of every dollar donated directly funds transformational clinical trials around the world.

$90
MILLION RAISED FOR INNOVATIVE CLINICAL TRIALS

9,000+
PATIENTS ENROLLED IN GATEWAY-FUNDED STUDIES

99 CENTS
OF EVERY DOLLAR DIRECTLY FUNDS RESEARCH

50+
ACTIVE STUDIES FOR CANCERS OF ALL TYPES

190+
CANCER CLINICAL TRIALS FUNDED WORLDWIDE

CANCER: A GLOBAL PUBLIC HEALTH CHALLENGE

More than 18 million people in the world are diagnosed with cancer annually.

Cancer accounts for 9.6 million deaths worldwide each year.

In the U.S., more than 1.8 million new cancer diagnoses are expected to occur in 2020.

This year it is estimated that more than 600,000 deaths in the U.S. will be attributed to cancer.

Sources: National Cancer Institute Surveillance, Epidemiology, and End Result Program (SEER) Study; World Health Organization data reported for 2018.
In these extraordinary times I offer two simple words: THANK YOU. On behalf of patients, families and physician-researchers around world, thank you for supporting Gateway for Cancer Research. Your investment is making possible the transformative clinical research trials that will create a world where cancer patients feel better, live longer, and conquer cancer TODAY!

For nearly three decades, Gateway has been a leader on the frontlines in the fight against cancer. Gateway funds early stage, pioneering, patient-centered studies that lead to groundbreaking new therapies that make a measurable, meaningful difference in patients’ lives. Thanks to your generous support, so many facing cancer live life feeling better every single day.

At Gateway, everything we do is always and only about the patient, and never has our mission been more urgent than it is today.

Cancer does not discriminate, and Gateway remains committed now more than ever to the patients we serve. Their lives depend on us, and our urgent cause is to deliver breakthrough cancer clinical trials to patients – NOW!

With you, Gateway will fulfill our shared vision to create a world in which a cancer diagnosis is no longer feared.

As always, with deepest gratitude and appreciation,

Richard J Stephenson
Chairman of the Board
Gateway for Cancer Research

“At Gateway, everything we do is always and only about the patient, and never has our mission been more urgent than it is today.”
A MESSAGE FROM THE PRESIDENT

At Gateway for Cancer Research we are driven by passion and a sense of urgency toward a single purpose: fund transformational early-stage clinical trials that help patients feel better and live longer as we shape a world in which a cancer diagnosis is no longer feared.

2020 was a year like no other. The global COVID-19 pandemic significantly impacted the clinical research enterprise. Far too many facing cancer lost access to promising investigational therapies as cancer centers around the world suspended clinical trials and reallocated resources to pandemic response.

Extraordinary times call for extraordinary measures. Gateway quickly addressed the unprecedented challenge the pandemic posed to clinical research and the health and well-being of those living with cancer by creating an innovative research funding program with one goal in mind: to bring the clinical trial to the patient, not require the patient to go to the trial. The new funding initiative supports “decentralized” clinical research studies leveraging technologies like telemedicine, wearables, remote monitoring and electronic consent to better ensure patient access to life-saving investigational therapies.

The response from the world’s cancer research community has been equally extraordinary. We are inspired by their innovation and ingenuity in adapting the traditional clinical trial model in order to put patients at the center of study design. With patients as our central focus, our organization is prepared to fuel the engine of scientific discovery through the pandemic and beyond.

As always, our success is dependent upon the generosity of supporters who are inspired by the depth and breadth of our mission and share our vision for the future. At this extraordinary moment in world history, we launched the Extraordinary Measures campaign to ensure that we continue to meet the unprecedented needs of cancer patients everywhere.

The last year has been one of remarkable discoveries and accomplishments. None of it would have been possible without you, our extraordinary and generous donors. On behalf of the entire Gateway team and the patients we are privileged to serve, thank you for your commitment and your partnership.

Together, we can and will persevere in our quest to end cancer as we know it, bringing transformational therapies and breakthroughs to all those we serve overcoming cancer.

Warm regards,

Michael Burton
President and CEO
Gateway for Cancer Research
The incredible “Studio 54” Cures Gala was a spectacular success, with actress and comedian Melissa Peterman serving as emcee and dazzling entertainment from artists CeeLo Green, The Sugarhill Gang and Tony Vincent, while raising an impressive $4.2 million for cancer research.

Dr. Stacie J. Stephenson, Vice Chair, Gateway for Cancer Research, and Richard J Stephenson, Founder and Chairman of Gateway, served as hosts for this amazing evening, which honored Kristen Hertel and Muneer Satter of the Satter Foundation as recipients of the inaugural Global Humanitarian Award. Muneer Satter and his wife Kristen share an approach to philanthropy rooted in the philosophy of empowering the powerless, and as generous supporters of Gateway help empower clinician-scientists working tirelessly to give patients access to transformational therapies.

The true stars of the Studio 54 Cures Gala were the patients who shared their inspiring stories of healing, hope and survivorship through Gateway-funded trials.

Kent Thomas was diagnosed with acute myeloid leukemia. After one month participating in a Gateway-funded clinical trial of a new therapeutic at the University of California – San Francisco, there was not a trace of cancer in Kent’s blood.

Luke Carusillo was just four years old when he was diagnosed with a rare, inoperable brain tumor. After 12 weeks in a Gateway-funded trial at New York University, Luke’s tumor shrank by half, and ultimately shrank by 90%. He was able to return to playing sports and enjoying time with his family.

Maddy Oliver was diagnosed with osteosarcoma, a type of bone cancer, when she was 17. Maddy participated in a Gateway-funded clinical trial at Children’s Hospital of Philadelphia, and recently celebrated five years cancer-free.

Gateway extends our deepest gratitude to Dr. Stacie J. Stephenson, Mr. Richard J Stephenson and generous donors for this unforgettable event, as we advance our vital cause to bring breakthroughs to the bedside for courageous patients around the world overcoming cancer.

VINO CON STELLE

While we were unable to gather for our annual Vino con Stelle event in 2020, please save the date for an unforgettable evening of wine under the stars on April 23, 2021 in Scottsdale, Arizona as we continue pressing forward, demanding cures and fighting to end cancer as we know it through Gateway for Cancer Research. Though this year will surely be a departure from our normal celebration, we are committed to creating a safe yet entertaining environment for all to enjoy.

Curated wine selections, second to none entertainment, and exciting live auction bidding opportunities will be available for all to enjoy - all in support of fighting this pervasive disease - cancer. We appreciate your support of this premiere signature event, and our vision to create a world in which a cancer diagnosis is no longer feared.
EXTRAORDINARY TIMES CALL FOR EXTRAORDINARY MEASURES

For the nearly 5,000 people every day who receive a cancer diagnosis, the global pandemic has dealt a double dose of complexity and heartache. COVID-19 has limited patient access to clinical trials—research that can make a world of difference for those facing cancer. At Gateway, we find this outcome troubling and unacceptable, and remain steadfast in our guiding principle that it is always and only about the patient. Our goal is clear: to bring the clinical trial to the patient, not require the patient to go to the trial.

To address the impact of the pandemic on patient access to clinical studies, Gateway is focused on funding innovative home-based clinical research studies that better ensure that investigational therapies remain accessible during the pandemic and beyond, including telemedicine, wearables, remote monitoring, electronic consent, and mobile nurse management.

Gateway has launched Extraordinary Measures, a combined grantmaking and fundraising campaign unlike any our organization has carried out in its nearly 30-year history, to help bring lifesaving care to the doorsteps of cancer patients everywhere.

Gateway Concierge, the most elite giving tier of the campaign, is an innovative program linking philanthropists that want to make a difference in the fight against cancer with renowned researchers who can deliver results. Through Concierge, Gateway tailors a research program reflecting the passions and philanthropic intentions of benefactors, putting them at the center of a compelling donor experience. This spring, Gateway received the first Concierge gift in the amount of $250,000 from Palm Beach-based philanthropist Raj Mantena.

To learn more and meet the moment for this extraordinary campaign, please visit gatewaycr.org/em.

“In the midst of every crisis, lies great opportunity.”
Albert Einstein

EXTRAORDINARY TIMES CALL FOR EXTRAORDINARY MEASURES

For the nearly 5,000 people every day who receive a cancer diagnosis, the global pandemic has dealt a double dose of complexity and heartache. COVID-19 has limited patient access to clinical trials—research that can make a world of difference for those facing cancer. At Gateway, we find this outcome troubling and unacceptable, and remain steadfast in our guiding principle that it is always and only about the patient. Our goal is clear: to bring the clinical trial to the patient, not require the patient to go to the trial.

To address the impact of the pandemic on patient access to clinical studies, Gateway is focused on funding innovative home-based clinical research studies that better ensure that investigational therapies remain accessible during the pandemic and beyond, including telemedicine, wearables, remote monitoring, electronic consent, and mobile nurse management.

Gateway has launched Extraordinary Measures, a combined grantmaking and fundraising campaign unlike any our organization has carried out in its nearly 30-year history, to help bring lifesaving care to the doorsteps of cancer patients everywhere.

Gateway Concierge, the most elite giving tier of the campaign, is an innovative program linking philanthropists that want to make a difference in the fight against cancer with renowned researchers who can deliver results. Through Concierge, Gateway tailors a research program reflecting the passions and philanthropic intentions of benefactors, putting them at the center of a compelling donor experience. This spring, Gateway received the first Concierge gift in the amount of $250,000 from Palm Beach-based philanthropist Raj Mantena.

To learn more and meet the moment for this extraordinary campaign, please visit gatewaycr.org/em.
WAYS TO GIVE
There are many ways to support Gateway’s vital cause.

**Event Sponsorship**
Sponsor a Signature Event and make a meaningful impact in the fight against cancer.

**Make a Donation**
Fund any amount to help Gateway advance its vision of shaping a world in which a cancer diagnosis is no longer feared.

**Tribute Gifts**
Show how much your friend or loved one means to you by making a donation in their honor.

**DIY Fundraiser**
Gateway provides all the resources you need for a successful event.

**In-Kind Gifts**
Gifts of merchandise or experiences create excitement at events and provide impactful marketing exposure.

**Stocks**
Gifts of stock will help continue Gateway’s funding of lifesaving research.

**Life Insurance**
Create an inspirational legacy by naming Gateway as a beneficiary of a life insurance policy that you and your family may no longer need.

**Wills and Bequests**
Include Gateway to create a lasting testament to your giving.

**Fundraise for Cancer Research from Home!**
A long-time cause partner, ONEHOPE has introduced new ways to fundraise for Gateway from home. Connect with friends and loved ones by hosting a virtual wine tasting party, and 10% of eligible wine purchases directly fund cancer research. For more information visit OneHopeWine.com/host.

**Charitable Trusts**
Make a difference by directly supporting cancer trials.

**Corporate Social Responsibility Partner**
Share your passion for funding breakthrough cures through support from your organization.

**Volunteering**
Give the gift of your time by joining a committee or attending an event.
FUNDING TODAY FOR MORE TOMORROWS

Gateway for Cancer Research invests in next generation science—research that has strong potential for a significant breakthrough in cancer care. The Gateway Research team oversees multiple grant programs that enable the organization to impact promising areas of inquiry in the oncology field. Through these programs, Gateway is instrumental in bringing to the bedside new cancer treatments and therapies that make a difference for patients, potentially changing the standard of care and enhancing quality of life.

Decentralized Clinical Trials Initiative (DCTI)

Gateway is committed to funding cancer research to ensure patients have access to critical cancer treatment. Gateway announced its DCTI program in 2020, attracting great interest from many of the world’s top cancer researchers. In July, Gateway awarded its first decentralized grant to Sameek Roychowdhury, MD, PhD, of The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute for his early phase clinical trial that is delivering the molecular profiling to the doorsteps of patients with certain rare solid tumor cancers. Patients will be assessed and monitored via telehealth.

Gateway Discovery Grant Program

Established by a scientific partnership with Conquer Cancer®, the ASCO Foundation, this prestigious grant funds a compelling area of inquiry with a grant award of $1.5 million every two years. The next Discovery Grant award will be focused on addressing cancer health disparities related to age, race and other socioeconomic factors. This year, internationally renowned cancer researcher and clinician David C. Linehan, MD, of the University of Rochester and Wilmot Cancer Institute, was awarded the inaugural Gateway Discovery grant for his pancreatic cancer study examining the use of a novel immunotherapy treatment protocol. To learn more, please visit gatewaycr.org/for-researchers/discovery-grant.

“The most exciting thing about our study is that it proves a better treatment may be attainable. We can take a patient who has actively growing, advanced, metastatic glioblastoma, and we can see regression of all lesions. To date, that’s unheard of.”

David C. Linehan, MD, Gateway-funded researcher and oncologist.

Young Investigator Award (YIA)

This grant, in partnership with Gateway and Conquer Cancer®, the ASCO Foundation, is awarded annually to a promising early-career investigator advancing quality early-phase clinical research.

Rising Tide Foundation

Gateway provides scientific peer review support and post-award grant management services to the portfolio of therapeutic grants from the Rising Tide Foundation® based in Switzerland.
A Gateway-funded clinical trial is pioneering a new treatment alternative and opening a gateway to hope for women over 60 who are diagnosed with an aggressive form of breast cancer.

Patients with HER2-positive breast cancer test positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein normally controls healthy breast cell growth, division and repair; however, when it is overexpressed it promotes the rapid growth of breast cancer cells. As a result, patients with HER2-positive breast cancer face a higher and earlier risk of cancer recurrence than those with other breast cancer subtypes.

One in five newly diagnosed HER2-positive breast cancer patients is age 60 or over, and that number is expected to increase as much as 50 percent in the coming decade as the U.S. population ages. However, older women have been underrepresented in clinical trials for new therapies in part because they experience more treatment-related toxicity than younger patients.

To address this inequity, Gateway-funded researcher Rachel Freedman, MD, MPH, professor of medicine at Harvard Medical School and medical director of Dana-Farber Cancer Institute Cancer Care Collaborative is leading the first clinical trial for women over 60 with HER2-positive breast cancer.

In the ATOP Phase II clinical trial Dr. Freedman and her colleagues are examining the use of an investigational drug called T-DM1 which targets HER2-positive breast cancer directly and limits exposure of chemotherapy toxins to the rest of the body. They also will look at age-related biomarkers, geriatric assessments and quality of life issues, providing a wealth of information about this under-studied patient population. Preliminary results from an earlier phase of the study show excellent outcomes, suggesting Dr. Freedman’s approach holds promise for older women with this aggressive breast cancer.

“We want to address the knowledge gap that exists. Our hope is that this trial expands our knowledge so we can more effectively treat our mothers, grandmothers, aunts, sisters and friends.”

Rachel Freedman, MD, MPH, Gateway-funded researcher and oncologist
PATIENT SPOTLIGHT: LIESEL

At 16, Liesel was her high school class valedictorian, played varsity sports, and was preparing for an Ivy League college career. While she had experienced severe migraines since she was 14, her pediatrician attributed them to the pressures of her extracurricular activities and academics. Then, a routine eye exam in July 2016 revealed an irregularity in one of Liesel’s eyes. In the hospital emergency department, an MRI revealed the cause of her migraines - a ping pong ball-sized tumor in her brain.

Liesel was admitted to Seattle Children’s Hospital where pediatric neuro-oncologist Sarah Leary, MD, was leading a Gateway-funded clinical trial that would change Liesel’s life. Dr. Leary was investigating the safety of BLZ-100, a drug commonly referred to as tumor paint because it adheres to tumor cells and causes them to glow under special lights. This enhances a surgeon’s ability to differentiate tumor cells from normal tissue, thus preserving as much healthy tissue as possible. Using Dr. Leary’s innovative tumor paint protocols, surgeons successfully removed Liesel’s tumor without causing irreversible damage to her brain.

Three weeks after surgery, Liesel returned home, determined to start her senior year in August. Despite some moments of short-term memory loss, Liesel continued to heal, resumed playing sports, and headed off to Harvard University the following fall to pursue her dream to study biomedical engineering.

“This journey has made me a more empathetic person. I’ve always been confident in my abilities, but this experience provided an unexpected test. I have been deeply humbled and am more grateful. I rejoice that I am alive and capable.”

Liesel
Funded Researchers

Hisham Abdel-Azim
Children’s Hospital Los Angeles

Bryan Allen
University of Iowa

Dario Altieri
The Wistar Institute

Charalambos Andreadis
University of California, San Francisco

Rebecca Auer
Ottawa Hospital Research Institute, Canada

Nilofer Azad
Johns Hopkins University

Muhammad Beg
University of Texas Southwestern Medical Center

Michael Bishop
St. Jude Children’s Research Hospital

Amol Ghia
MD Anderson Cancer Center

Rachel Blitzblau
Duke University

Christine Brown
City of Hope

Alexandra Carey
Boston Children’s Hospital

Nelson Chao
Duke University

Toni Choueiri
Dana-Farber Cancer Institute

Christopher Cogle
University of Florida

Lorenzo Cohen
MD Anderson Cancer Center

Robert L. Coleman
MD Anderson Cancer Center

Miriam Cremer
Cleveland Clinic Foundation

Stella Davies
Cincinnati Children’s Hospital Medical Center

Khanh Do
Dana-Farber Cancer Institute

Rachel Freedman
Dana-Farber Cancer Institute

David Gerber
University of Texas Southwestern Medical Center

Olivia Pagani
Institute of Oncology of Southern Switzerland (OSI)

Sumanta Pal
City of Hope

Emanuel Petricoin
George Mason University

Dana Rathkopf
Memorial Sloan Kettering Cancer Center

Nathan Robison
Children’s Hospital Los Angeles

Rizwan Romee
Dana-Farber Cancer Institute

Sacha Rothschild
University Hospital Basel

Jeffrey Rubnitz
St. Jude Children’s Research Hospital

David Schwartz
John Theurer Cancer Center at Hackensack University

Steven Devine
Be the Match Foundation

Ajay Sheshadri
MD Anderson Cancer Center

Nizar Tannir
MD Anderson Cancer Center

David Ting
Massachusetts General Hospital Cancer Center

Linda Vahdat
Memorial Sloan Kettering Cancer Center

Abhinav Doel, MD
Karmanos Cancer Institute

Anupam Verma
University of Utah

Alan Wayne
Children’s Hospital Los Angeles

Shiao-Pei Weathers
MD Anderson Cancer Center

Lei Zheng
Johns Hopkins University

Nancy Gordon
MD Anderson Cancer Center

Tanja Gruber
St. Jude Children’s Research Hospital

Bryan Hennessy
Royal College of Surgeons

Lee Jones
Memorial Sloan Kettering Cancer Center

Isaac Kim
Rutgers, The State University of New Jersey

Yaacov Lawrence
Sheba Medical Center

Sarah Leary
Seattle Children’s Hospital

David Levy
Cleveland Clinic

David Linehan
University of Rochester

Maryam Lustberg
The Ohio State University

Nicholas Mach
Geneva University Hospital

Christoph Mamot
Cantonal Hospital Aarau

James Markert
University of Alabama at Birmingham

Janice Mehnert
Rutgers, The State University of New Jersey

Parinda Mehta
Cincinnati Children’s Hospital Medical Center

Sabine Mueller
University of California, San Francisco

Aung Naing
MD Anderson Cancer Center

Fariba Navid
Children’s Hospital Los Angeles

Adrian Ochsenbein
University Hospital, Inselspital

FUNDED RESEARCHERS
THANK YOU TO OUR DONORS

On behalf of the patients, families, and clinician-scientists around the world for whom your donations are making a difference, thank you for supporting Gateway for Cancer Research and the quest to create a world in which a cancer diagnosis is no longer feared.

Every donor and every dollar make a meaningful difference in the fight against cancer. Your generosity is making possible some of the most innovative, transformational clinical trials that will end cancer as we know it.

CHAIRMAN’S CIRCLE
$100,000 and Above
Mr. Richard J and
Dr. Stacie J. Stephenson
International Private Bank
Cancer Treatment Centers of America®
Clune Construction Company
The Edgewater Funds,
Jim and Andi Gordon
Ms. Nelda Mae Hobbs
International Capital &
Management Company
Mr. and Mrs. Raj Mantena
Marsh Management Services
Rising Tide Foundation
Satter Foundation
Dr. and Mrs. Christopher Stephenson
Templer Family Foundation

CTCA Phoenix
Mr. and Mrs. Timothy J. Danis
David&Goliath
The Greg and Anna Brown
Family Fund
Katten Muchin Rosenman LLP
Mr. and Mrs. Thomas E. Lechowicz
Mr. and Mrs. Robert Mayo
Mr. Bill Pope
The Shirley C. Caris Family Foundation
Shawn and Morgan Stephenson

CIRCLE OF INNOVATION
$10,000 - $24,999
Abbvie, Inc.
Ahead
Mr. Jacob Alcauskas
Bank of America Merrill Lynch
The Bill Bass Foundation
BLG Capital Advisors
Mr. and Mrs. Michael Bond
Mr. and Mrs. Michael Burton
Celgene
Mr. and Mrs. Gyasi Chisley
CIBC
Citi Private Bank
Conquer Cancer®,
the ASCO Foundation
Denton
Mr. and Mrs. Zachary Doehlia
Mr. and Mrs. Timothy Flanigan
Mr. and Mrs. Christopher B. Galvin
Mr. and Mrs. Bill Grogan
Mr. and Mrs. James Grogan
Harbour Group Investments
Mr. and Mrs. Charles Harris
ITW
The Kelly Foundation
Mr. and Mrs. Matthew Kibbe
Litchfield Advisors Incorporated

Mr. and Mrs. Bruce S. Lubin
Mr. and Mrs. Dean Lurker
Mr. and Mrs. Dennis Lynde
The Honorable Stephen Manrose and
Mrs. Janet Horn
Maxor National Pharmacy Services
McDermott Will & Emery
McGuire Woods LLP
McKinsey & Company Inc.
Merkle Health
Phoenix Children’s Hospital
Mr. and Mrs. Philip Picchiotti
Bill Sasso, Stradley Ronon
Mr. and Mrs. David Scheible
Dr. and Mrs. Julian Schink
Servier Pharmaceuticals
Sheridan Capital Partners
Talent + Inc.
Drs. Ailyn and Bradford Tan
Vizient
Fei Wang & Michael DiCosola,
UBS Private Wealth
Wells Fargo
Dr. and Mrs. Peter C. Yesawich

CIRCLE OF HOPE
$1,000 - $9,999
Dr. Syed Abutalib
Aetna Foundation, Inc.
Mr. Jonathan Alde
Ms. Roxana Aleksic
Mr. David Allen
Arizona Diamondbacks
Assuance Agency, Ltd.
Mr. and Mrs. Steve Baer
Dr. Peter Baik
Mrs. Rachel Bailey
Dr. Frank Balis
Mr. and Mrs. Charles Bartels
Dr. Jason Beland
Mr. Steve Sobkowiak
Dr. Marnee and Mr. David Spierer
Mr. and Mrs. James V. Stibgen
Mr. Brian Storms
Mr. and Mrs. Brian Stroup
Mr. Daniel Taylor
Team National Hope Foundation
Mr. and Mrs. Shane Thompson
Mr. Karl Tillemann
Mr. Craig Tobin
Dr. and Mrs. E. Steven Townsend
Mr. and Mrs. Bernard R. Tresnowski
Dr. and Mrs. Kevin Tulipana
Mr. Matt Tuthill
The Terri Ucci Family Foundation
Mr. and Mrs. Sam Van Norman
Drs. Glynis and Pankaj Vashi
Dr. and Mrs. David Visco
Mr. and Mrs. Shane Thompson
Mr. Karl Tillemann
Mr. and Mrs. Lou Weishbach
Mr. Gene Weisskopf
Ms. Jenni Westrich
Ms. Caroline Whorton
Mr. and Mrs. Cornel Williams
Mr. and Mrs. Alan W. Wilson
Ms. Anne Witort
Dr. and Mrs. Larry Wofford
Mr. and Mrs. Michael Wozniak
Mr. Jeff Wright
Mr. Robert Wynn
Dr. Alan Yahanda and
Dr. Pamela Thomas
Dr. and Mrs. Kenny Yoo
Dr. Mark Zafereo
Mr. and Mrs. Wendelin Zellmayer

Mrs. Jo Ann Andrews
Ms. Franiska Ansu
Mr. Chris Ardolino
ARRT Purchases
Ms. Susan Avila
Mr. and Mrs. Steve Baer
Ms. Juliana Baer
Ms. Emily Bailey
Mr. Russ Bakalar
Mr. Chris Bakes
Bank of America Charitable
Foundation
Dr. Maan Barhoum
Mr. Jim Barnett
Ms. Dwendolyn Barnhart
Mr. Ryan Bartels
Mr. Sean Bartlett
Mr. Chuck Baucum
Mr. and Mrs. Edward Baumgart
Ms. Elle Bausch
Mr. Robert J. Beggin
Ms. Jill Bell
Benco Family Foundation
Ms. Leslie Beyer
Ms. Debbie Biancalana
Blue Springs Metal
Mr. Randy Bosman
Ms. Lisa Bowen
Ms. Kathy Bowen
Mr. Donald Bowling
Ms. Jamie Bradford
Ms. Ann Brown
Brown Brothers Harriman Co.
Mr. Todd Buckner
Ms. Devon Buesking
Ms. Lisa Buetow
Mr. Emmett Bullen
Mr. Ethan Burgard
Ms. Morgan Burkemper
Mrs. Annette Busleta
Ms. Alaina Butler
Mr. John Butler
Ms. Maria Cabanillas
Mr. Mark Caisey
Mr. John Calabrese
Ms. Dorothy Calley
Ms. Laura C. Camarda
Mr. Daniel Cameron
Mr. and Mrs. Victor Caricato
Mr. William Caristedt

CIRCLE OF FRIENDS
$100 - $999
Ms. Anna Adair
Dr. Sramila Aithal
Mr. and Mrs. Ken Alexander
Ms. Allison Alford
Mr. and Mr. Jeremy Alonso
Amazon Smile
Ms. Denean Ambersley
American Legion Auxiliary
Ms. Margaret Anderson

Mr. Jones Carlton
Ms. Claudia Carlucci
Ms. Tonia Carpenter
Ms. Laurel Charles
Mr. Filemon Chavarria
Ms. Nghia Che
Children’s Crisis Treatment Center Inc.
Mr. Ned Childs
Ms. Lorraine Chisari
Mr. William Chukerman
Mr. Richard Chumley
Mr. Joseph Ciccone
Cobank
Mr. Michael Cohen
Ms. Karen Cohen
Ms. Lisa Cohen
Ms. Lori Cole
Community Foundation of
Central Georgia
Ms. Kerry Contini
Ms. Shirl Coons
Ms. Jola Cope
Mr. and Mrs. Fred A. Cottini
Mr. and Mrs. William Cox
Ms. Janet Crawford
Ms. Kimberly A. Crown
Ms. Barbara Cunningham
Ms. Madeline Dardanes
Mr. Chris Dardanes
Mr. Gordon Davis, Jr. and
Mrs. Rachel Ellefson
Ms. Paula Davis
Ms. Marie DeGrave
Mr. Vincent DeGregorio
Mr. Patrick Dellapenta
Mr. and Mrs. Richard Dickson
Dr. Nausheen Din
Ms. Susan Donahue
Ms. Elaine Doremus
Ms. Tammy Doss
Ms. Lauren Dower
Mr. Jeff Dulla
Mr. William Dunkel
Mr. Timothy Dunneback
Mr. Adam Dupras
Mr. Richard Duty
Ms. Maxie Neal Dye
Ms. Wes Eads
Ms. Gina Eaves
Mr. Eric Eckerman
Mr. Wallace Madden
Mr. Gabriel Magee
Ms. Victoria Magnesi
Mr. and Mrs. Chester Mahan
Ms. Michelle Maison
Mr. Chris Malo
Mr. Phil Manke
Mr. Gerald Marazoni
Ms. Donna Marchant
Ms. Erica Marchese
Ms. Mary Frances Marino
Ms. Cathy T. Marquez
Ms. Annamarie Martinez
Ms. Andy Martinez
Mr. Roberto Martinez
Mr. Troy Maschmeyer
Mr. and Mrs. Doug Van Mater
Mr. Cameron Mathison
Ms. Jean Matlachowski
Mr. Tyler Max
Ms. Lori McAninch
Ms. Kathleen P. McAuliffe
Mr. Claydean McCollon
Dr. Patrick McCarthy and
Mrs. Lisa Keane McCarty
Mr. John McClue
Mr. John McCutcheon
Ms. Pamela McDuff
Mr. and Mrs. Paul McGuire
Ms. Janice McLain and
Ms. Lori Rolnick
Ms. Cindy McLaughlin
Mrs. Darlene Meese
Ms. Lorrie Meserole
Mrs. Christine Michels
Mr. Robert Miles
Mr. Gary Miller
Mr. Mindi Miller
Mr. Harris Miller
Ms. MaroLee Miller
Mr. Jake Mitchell
Ms. Donna Mo
Mr. Phillip Mohr
Mr. Maxwell Mohr
Ms. Colleen Monahan
Mr. Ivan Montes
Mr. Craig Moran
Ms. Dara Morehead
Mr. Rod Morganstein
Mr. Larry Moser
Mr. Jibrann Muhammad
Ms. Barbara Muller
Ms. Colleen Murillo
Mr. and Mrs. James Murphy
Mr. Anthony Musso
Mr. and Mrs. Michael Myers
Mr. and Mrs. Paul Nachowicz
Mr. Miroslav Neskovic
Netsmart Technologies, Inc.
Mr. Brandon Newman
Ms. Debra Newsanger
Northern Middlesex Council
of Governments
Ms. Joanne Obrien
Ms. Morgan O’Connor
Mr. Thomas O’Grady
Mr. Andrew Olasz
Dr. Michael Olsen
Mr. Leo Olsen
One4All Charitable Fund
Mr. and Mrs. Ron Palecki
Mr. Charles Parker
Mrs. Sarah Parker
Ms. Judith Parnock
Patrick Automotive Group
Ms. Chris Pawlowski
Mr. and Mrs. Larry Penix
Mr. Geoffrey Perlman
Mrs. Stacy Petersen
Ms. Carolyn Peterson
Mr. and Mrs. Scott Pfeifer
Ms. Julia Pfeifer
Mr. Duc Phan
Ms. Kathy Pipps
Ms. Wendy Poage
Mr. Daniel Pope
Ms. Anne Poppe
Ms. Rose Prete
Mr. and Mrs. Ken Priest
Mrs. Bonnie Quire
Ms. Stella Raasch
Mr. Andrew Radiff
Ms. Subramanian Raman
Mr. Eric Ramos
Ms. Marly Ramsey
Ms. Cynthia Ransom
Mr. and Mrs. Ed Rauser
Ms. Chance Reed
Ms. Deborah Reid
Ms. Alekzandrea Reyes
Mr. Bob Reynolds
Ms. Donna Richards
Mrs. Lorraine Richardson
Ms. Jill Riddle
Mr. Michael Rigali
Ms. Beverly Roben
Ms. Andrea Robertson
Ms. Deborah Robles
Ms. Ann Roghair
Mr. Joshua Rojas
Ms. Marge Roman-Bates
Rosewood Apartments
Mrs. Sara Ross
Mr. Paul Rossi
Ms. Melanie Rousseau
Mr. Kevin Rueff
Mr. Michael Sack
Mr. James Sandoval
Ms. Marisol Santa
Mr. Joseph Scavone
Ms. Leslie Schecter
Mr. Eugene Schempp
Ms. Kari Schiffman
Mr. and Mrs. Gerald Schinkel
Mr. Steven Schmidt and
Ms. Priscilla Puhl
Mr. and Mrs. Bryan Schmidt
Mr. Todd Schoenfeld
Mr. John Schrieffer
Ms. Julie Schumann
Ms. Julie Schummer
Mr. Chad Schwartz
Mr. David Schwartz
Mr. Michael Scolari
Mr. Terence Scott
Ms. Martha Seabrooks
Mrs. Michelle Searcy
Mr. Robert Seidel
Ms. Anne Seneca
Mr. and Mrs. John Senft
Ms. Pamela Sergent
Mr. David Sewall
Mr. Walter Shafer
Ms. Marianne Shane
Ms. Sandra Short
Mr. and Mrs. Shad Sias
Georgia Sibley
Sideouts Bar & Eatery
Ms. Lili Silva
Ms. Kim Simmons
Ms. Amy Singley  
Skender Construction LLC  
Ms. Reni Slepka  
Mr. Alfred Russell Smiley  
Mrs. Linda Smith  
Mr. Gary Smith  
Mr. Dean Smith  
Mr. Stephen Smith  
Mr. James Snyder  
Dr. William Soper  
Ms. Bruna Srb  
Ms. Susan Staley  
Mr. Thomas Stavredes  
Mr. Sean Steele  
Ms. Carolyn Stepp  
Ms. Carole Stewart  
Mr. Gregory Stigall  
Mr. Gregg Stickland  
Mr. Max Strommen  
Mr. James S. Stuart  
Mr. Toby Suckow  
Mr. Christopher Surdenik and  
Mrs. Candy Vazquez  
Mr. Greg Sutton  
Mr. Charles Sweeney  
Mr. Ira Swidler  
Mr. Kurt Tamaru  
Mr. Steve Taylor  
Dr. Matthew Taylor  
Ms. Margaret Taylor  
Honorable Elliott Teller  
Ms. Carolyn S. Tetzlaff  
Ms. Tracy Tetzner  
Ms. Kristi Thompson  
Colonel James D. Thompson  
Mr. Todd Thompson  
Mr. and Mrs. Stephen Thompson  
Mr. and Mrs. Tim Thompson  
Ms. Susan Thorndyke  
Thrivent Financial for Lutherans  
Foundation  
Ms. Mica Timothy-Gooding  
Ms. Dani Tucker  
Ms. Jennifer Tullius  
Mr. Thomas Tyng  
Mr. Josh Udelhofen  
Mr. and Mrs. Bryan Vaughn  
Ms. Joyce Vissichelli  
Ms. Sujatha Viswanathan  
Ms. Lisa Wagner  
Mr. Matthew Waldbusser  
Ms. Joan Walldan  
Mr. Caprice Walters  
Mr. and Mrs. Corey Walz  
Warehouse Services, Inc.  
Mr. and Mrs. Michael Weadock  
Mrs. Tiffany Weaver  
Dr. and Mrs. Jeffrey Weber  
Mr. & Mrs. Wayne Wendel  
WHB, Inc.  
Ms. Maryrose N. White  
Dr. Samuel Willens  
Ms. Jan Williams  
Mrs. Jodi Willingham  
Ms. Keely Winiger  
Mr. William Winterfeld and  
Ms. Alicia Cooke  
Mr. Jeff Wolf  
Dr. Zaho Xiao  
Ms. Aimee Yaboni  
Mr. and Mrs. Ryan Zafereo  
Ms. Janine Zaremba  
Mr. William Zarvis

“Never again am I going to look at a birthday and say, ‘I can’t believe I’m going to be another year older.’ Now I’m saying, ‘I’m so glad to be another year older!’”
Beth, lymphoma patient in a Gateway-funded trial

These donations represent cash gifts from July 1, 2019 through June 30, 2020. Gateway has made every attempt to include and highlight the generosity of our donors. If your name is not included on this list and you made a donation of $100 and above, please let us know.
LEADERSHIP

BOARD OF DIRECTORS

Richard J Stephenson  
CHAIRMAN
Dr. Stacie J. Stephenson  
VICE CHAIRMAN
Fred DeGrandis  
SECRETARY
Timothy Flanigan  
ASSISTANT SECRETARY
Tony Festa  
TREASURER

Amy Belew
Tawnya Bond
Michael Burton
(ex officio)
Joe Caltabiano
Jake Goldstein
Dr. Emanuel Petricoin
Deniz Razon

Edwin Roberson
Mary Lou Smith
Dr. Satish Tadikonda

RESEARCH AND GRANTS COMMITTEE

BOARD OF DIRECTORS

LIAISON
Dr. Emanuel Petricoin
Mary Lou Smith
Deniz Razon

MD/PHD
Dr. Sameek Roychowdhury – Peer Review, Chair
Dr. Edward Kim
Dr. Alberto Pappo
Dr. Tim Fleming
Dr. Ronald Morton
Dr. Jordi A. Rodon
Dr. Vivek Subbiah

PATIENT ADVOCATE
Rich Rieger
ND
Dr. Lise Alschuler
Dr. Judy Fluop

ASSOCIATES BOARD

Danny Cameron  
BOARD CO-CHAIR
Catherine Lyman  
BOARD CO-CHAIR
Corey Walz  
TREASURER
David Lauschke  
SECRETARY
Elle Bausch  
COMMUNICATIONS CO-CHAIR
Ashley Heibert  
COMMUNICATIONS CO-CHAIR
Lili Silva  
MEMBERSHIP & ENGAGEMENT CO-CHAIR
Christi Turner  
MEMBERSHIP & ENGAGEMENT CO-CHAIR
Lucy Dolya  
SPONSORSHIP CO-CHAIR
Robert Watson  
SPONSORSHIP CO-CHAIR
Neira Hot  
MISSION CONNECTION CHAIR

Dan Frett
TJ Gilboy
Emmanuel Lopez
Julia Pfiefer
Shelby Stephenson
Jillian Stevens
Max Strommen
Josh Udelhofen
# FINANCIAL HIGHLIGHTS

## Fundraising Revenue

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$1,268,828</td>
</tr>
<tr>
<td>Special Events</td>
<td>$4,057,598</td>
</tr>
<tr>
<td><strong>Total Fundraising Revenue</strong></td>
<td><strong>$5,326,426</strong></td>
</tr>
</tbody>
</table>

## Research Grants

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Awarded Grant Funds</td>
<td>$5,460,236</td>
</tr>
</tbody>
</table>

## Assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalent</td>
<td>$6,213,953</td>
</tr>
<tr>
<td>Pledges and Other Receivables</td>
<td>$184,219</td>
</tr>
<tr>
<td>Investments</td>
<td>$10,874,004</td>
</tr>
<tr>
<td>Prepaid Expenses</td>
<td>$46,550</td>
</tr>
<tr>
<td>Interests in Limited Partnerships</td>
<td>$8,350</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$17,327,076</strong></td>
</tr>
</tbody>
</table>

## Liabilities

<table>
<thead>
<tr>
<th>Liability</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accrued Grants</td>
<td>$10,214,159</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>$138,500</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td><strong>$10,352,659</strong></td>
</tr>
</tbody>
</table>

## Net Assets

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net Assets</strong></td>
<td><strong>$6,974,417</strong></td>
</tr>
</tbody>
</table>

## Total Liabilities and Net Assets

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td><strong>$17,327,076</strong></td>
</tr>
</tbody>
</table>
“THERE’S NOTHING BETTER THAN HOPE”